Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

141. Tumor suppressive roles of eugenol in human lung cancer cells

Tumor suppressive roles of eugenol in human lung cancer cells 29024500 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Tumor suppressive roles of eugenol in human lung cancer cells. 25-29 10.1111/1759-7714.12508 Eugenol, a natural compound available in Syzigium aromaticum (cloves), is exploited for various medicinal applications. Eugenol induces apoptosis and functions as an anti-cancer drug in several types of tumors. We investigated the tumor suppressive role (...) and potential mechanisms of eugenol in human lung cancer cells. Human embryonic lung fibroblast MRC-5 and lung cancer adenocarcinoma A549 cells were incubated with or without various concentrations of eugenol for 24 hours. Cell counting kit 8 and crystal violet staining assays were performed to detect cell viability. The cell migration and invasion abilities were also determined by wound healing and transwell assays. Finally, Western blotting assay was performed to examine the changes in lung cancer cell

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

142. Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes

Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes 29556585 2018 11 14 2452-1094 3 1 2018 Jan-Mar Advances in radiation oncology Adv Radiat Oncol Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes. 81-86 10.1016/j.adro.2017.10.002 The treatment of apical lung tumors with stereotactic body radiation therapy (SBRT (...) ) is challenging due to the proximity of the brachial plexus and the concern for nerve damage. Between June 2009 and February 2017, a total of 75 consecutive patients underwent SBRT for T1-T3N0 non-small cell lung cancer involving the upper lobe of the lung. All patients were treated with 4-dimensional computed tomography (CT)-based image guided SBRT to a dose of 40 to 60 Gy in 3 to 5 fractions. For dosimetric analysis, only apical tumors as defined by the location of the tumor epicenter superior to the aortic

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

143. Case report of 18F–fluorodeoxyglucose positron emission tomography‐computed tomography imaging of a patient with multiple endocrine gland metastases from small cell lung cancer

Case report of 18F–fluorodeoxyglucose positron emission tomography‐computed tomography imaging of a patient with multiple endocrine gland metastases from small cell lung cancer 28980762 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Case report of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography imaging of a patient with multiple endocrine gland metastases from small cell lung cancer. 167-170 10.1111/1759-7714.12523 Synchronous multiple (...) endocrine gland metastasis caused by small cell lung cancer (SCLC) is rare. A patient was investigated for primary cancer because of suspected brain metastasis on computed tomography (CT). Baseline 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT was positive in the lung and multiple endocrine glands (right thyroid, right breast, pancreatic body, right adrenal gland, and left ovary). Histopathology confirmed small cell lung cancer. The patient's symptoms were alleviated after

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

144. Survival significance of coexisting chronic obstructive pulmonary disease in patients with early lung cancer after curative surgery

Survival significance of coexisting chronic obstructive pulmonary disease in patients with early lung cancer after curative surgery 28976075 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Survival significance of coexisting chronic obstructive pulmonary disease in patients with early lung cancer after curative surgery. 19-24 10.1111/1759-7714.12507 The impact of chronic obstructive pulmonary disease (COPD) severity on survival after curative resection of early-stage (...) lung cancer (NSCLC) has not been sufficiently elucidated. We retrospectively reviewed 250 consecutive patients who underwent lobectomy with lymph nodal dissection for pathological stage I-II NSCLC. Among the COPD patients, 28 were classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1, 21 as GOLD 2, and one as GOLD 3. The cumulative overall survival (OS) of the non-COPD, GOLD 1, and GOLD 2-3 groups at five years was 90.7%, 85.7%, and 55.3%, respectively, (P < 0.0001), while

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

145. Screening for Lung Cancer Has Limited Effectiveness Globally and Distracts From Much Needed Efforts to Reduce the Critical Worldwide Prevalence of Smoking and Related Morbidity and Mortality

Screening for Lung Cancer Has Limited Effectiveness Globally and Distracts From Much Needed Efforts to Reduce the Critical Worldwide Prevalence of Smoking and Related Morbidity and Mortality 30241213 2018 11 14 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Screening for Lung Cancer Has Limited Effectiveness Globally and Distracts From Much Needed Efforts to Reduce the Critical Worldwide Prevalence of Smoking and Related Morbidity and Mortality. 1-7 10.1200/JGO.2017.1700016 (...) Oncol 101674751 2378-9506 J Natl Cancer Inst. 2000 Dec 20;92(24):1979-91 11121460 Lancet. 2017 May 13;389(10082):1885-1906 28390697 Tob Control. 2010 Apr;19 Suppl 1:i68-76 20382654 N Engl J Med. 2013 Jul 18;369(3):245-254 23863051 J Clin Oncol. 2014 Mar 10;32(8):768-73 24419137 Tob Induc Dis. 2009 Mar 26;5(1):6 19323826 N Engl J Med. 2014 Nov 6;371(19):1793-802 25372087 Tob Control. 2000 Mar;9(1):47-63 10691758 Lung Cancer. 2005 May;48(2):171-85 15829317 PLoS One. 2012;7(1):e29665 22238633 N Engl J

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

146. Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival

Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival 28450031 2017 04 28 2017 09 22 2017 09 22 1931-3543 152 3 2017 Sep Chest Chest Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival. 587-597 S0012-3692(17)30741-9 10.1016/j.chest.2017.03.059 Black patients with lung cancer diagnosed at early stages-for which surgical resection offers a potential cure-experience worse overall survival than do their white counterparts. We undertook a population-based study to estimate (...) the racial and ethnic disparity in death from competing causes and assessed its contribution to the gap in overall survival among patients with early-stage lung cancer. We collected survival time data for 105,121 Hispanic, non-Hispanic Asian, non-Hispanic black, and non-Hispanic white patients with early-stage (IA, IB, IIA, and IIB) lung cancer diagnosed between 2004 and 2013 from the Surveillance, Epidemiology, and End-Results registries. We modeled survival time using competing risk regression

EvidenceUpdates2017

147. [Trametinib (non-small cell lung cancer) - enefit assessment according to õ35a Social Code Book V]

[Trametinib (non-small cell lung cancer) - enefit assessment according to õ35a Social Code Book V] Trametinib (nicht kleinzelliges Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-16 [Trametinib (non-small cell lung cancer) - enefit assessment according to §35a Social Code Book V] Trametinib (nicht kleinzelliges Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-16 [Trametinib (non-small cell lung cancer) - enefit assessment (...) (non-small cell lung cancer) - enefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 52. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; trametinib Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im

Health Technology Assessment (HTA) Database.2017

148. [Pembrolizumab (non-small cell lung cancer) - addendum to Commission A17-06]

[Pembrolizumab (non-small cell lung cancer) - addendum to Commission A17-06] Pembrolizumab (nicht kleinzelliges Lungenkarzinom): Addendum zum Auftrag A17-06; Auftrag A17-28 [Pembrolizumab (non-small cell lung cancer) - addendum to Commission A17-06] Pembrolizumab (nicht kleinzelliges Lungenkarzinom): Addendum zum Auftrag A17-06; Auftrag A17-28 [Pembrolizumab (non-small cell lung cancer) - addendum to Commission A17-06] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab (nicht kleinzelliges Lungenkarzinom): Addendum zum Auftrag A17-06; Auftrag A17-28. [Pembrolizumab (non-small cell lung cancer) - addendum to Commission A17-06] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im

Health Technology Assessment (HTA) Database.2017

149. [Dabrafenib (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V]

[Dabrafenib (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V] Dabrafenib (nicht kleinzelliges Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Auftrag A17-17 [Dabrafenib (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V] Dabrafenib (nicht kleinzelliges Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Auftrag A17-17 [Dabrafenib (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dabrafenib (nicht kleinzelliges Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Auftrag A17-17. [Dabrafenib (non-small cell lung cancer) - benefit assessment

Health Technology Assessment (HTA) Database.2017

150. Expression of CXCR4 and VEGF‐C is correlated with lymph node metastasis in non‐small cell lung cancer

Expression of CXCR4 and VEGF‐C is correlated with lymph node metastasis in non‐small cell lung cancer 28925100 2018 03 20 2018 11 13 1759-7714 8 6 2017 11 Thoracic cancer Thorac Cancer Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer. 634-641 10.1111/1759-7714.12500 This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). Tumor specimens, lymph nodes (...) , and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcription-PCR and immunohistochemistry assays were conducted to evaluate messenger RNA (mRNA) and protein expression of CXCR4 and VEGF-C. Logistic regression analysis was performed to determine the independent risk factors for lymph node metastasis in NSCLC. CXCR4 and VEGF-C mRNA expression were observed in 78 (70.9%) and 64 (58.2%) lung cancer tissues, while CXCR4 and VEGF-C protein

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

151. Association between polymorphisms in microRNA target sites and survival in early‐stage non‐small cell lung cancer

Association between polymorphisms in microRNA target sites and survival in early‐stage non‐small cell lung cancer 28922562 2018 03 20 2018 11 13 1759-7714 8 6 2017 11 Thoracic cancer Thorac Cancer Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer. 682-686 10.1111/1759-7714.12478 A high-throughput mapping method of RNA-RNA interactions by crosslinking, ligation, and sequencing of hybrids (CLASH) can not only provide information (...) about canonical but also non-canonical interactions. We evaluated the associations between variants in microRNA target sites using CLASH data and survival outcomes of 782 early-stage non-small cell lung cancer (NSCLC) patients who underwent curative surgical resection. Among the 100 variants studied, two variants showed significant association with survival outcomes. The POLR2A rs2071504 C > T variant was associated with poor overall and disease-free survival under a dominant model (hazard ratio [HR

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

152. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study 29018574 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. e000214 10.1136/esmoopen-2017-000214 Some patients with advanced or recurrent, epidermal growth factor (...) receptor (EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to receive EGFR tyrosine kinase inhibitors (TKIs) beyond radiological progression. We analysed a cohort of 577 patients with EGFR M+ NSCLC, who had received a first-line EGFR-TKI. We classified patients according to clinical course and treatment patterns at Response Evaluation Criteria in Solid Tumors (RECIST) progressive disease (PD). We evaluated the period from RECIST PD to TKI discontinuation or clinical PD

ESMO open2017 Full Text: Link to full Text with Trip Pro

153. Salvage radiotherapy for regional lymph node oligo‐recurrence after radical surgery of non‐small cell lung cancer

Salvage radiotherapy for regional lymph node oligo‐recurrence after radical surgery of non‐small cell lung cancer 28906073 2018 03 20 2018 11 13 1759-7714 8 6 2017 11 Thoracic cancer Thorac Cancer Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer. 620-629 10.1111/1759-7714.12497 Currently, evidence-based guidelines for salvage therapy to treat mediastinal lymph node (LN) oligo-recurrence in post-resection non-small cell lung (...) Oncol Biol Phys. 1997 Mar 15;37(5):1079-85 9169816 Lung Cancer. 1995 Oct;13(2):121-7 8581391 Chest. 2013 May;143(5 Suppl):e278S-e313S 23649443 Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1100-5 19540063 J Thorac Oncol. 2007 Aug;2(8):706-14 17762336 Chest. 2013 May;143(5 Suppl):e314S-e340S 23649445 Lung Cancer. 1998 Apr;20(1):31-5 9699185 Eur J Cardiothorac Surg. 2016 Mar;49(3):847-53 26201958 Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1097-105 16682136 Int J Radiat Oncol Biol Phys. 1992;24

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

154. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis

Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis 30241202 2018 11 14 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. 1-7 10.1200/JGO.17.00059 Extensive-stage small-cell lung cancer (esSCLC) is an incurable disease and represents a therapeutic challenge because of its poor prognosis. Studies in prophylactic cranial irradiation (...) 101674751 2378-9506 Eur J Cancer. 1997 Oct;33(11):1752-8 9470828 Lung Cancer. 2002 Sep;37(3):271-6 12234695 Cancer. 2008 Apr 15;112(8):1827-34 18311784 Lancet Oncol. 2009 May;10(5):467-74 19386548 J Clin Oncol. 2009 Jan 1;27(1):78-84 19047288 N Engl J Med. 2007 Aug 16;357(7):664-72 17699816 J Clin Oncol. 1998 May;16(5):1954-60 9586915 N Engl J Med. 1999 Aug 12;341(7):476-84 10441603 N Engl J Med. 1992 Dec 3;327(23):1618-24 1331787 J Clin Oncol. 1990 Jan;8(1):48-56 2153196 J Clin Oncol. 2006 Mar 10;24(8

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

155. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Background Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more (...) ). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. Results Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8

NEJM2017

156. Ceritinib (Zykadia©) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer

Ceritinib (Zykadia©) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer McGahan, L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation McGahan, L. Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions Overall, ceritinib increased PFS and duration of response in untreated ALK-positive NSCLC, regardless of the presence or absence of baseline BM, relative to platinum-based chemotherapy

Health Technology Assessment (HTA) Database.2017

157. Atezolizumab (Tecentriq©) in previously treated non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq©) in previously treated non-small cell lung cancer (NSCLC) Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC) Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC) McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Atezolizumab (...) (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions There is no evidence regarding quality of life, patient reported outcome measures or patient reported experience measures to determine whether atezolizumab provides clinically significant improvement in the symptoms or severity of NSCLC. Results from the OAK (phase III) randomized, open-label trial

Health Technology Assessment (HTA) Database.2017

160. eUpdate ? Metastatic Non-Small-Cell Lung Cancer

eUpdate ? Metastatic Non-Small-Cell Lung Cancer eUpdate – Metastatic Non-Small-Cell Lung Cancer | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Join ESMO There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society Member Benefits See the full list of benefits that ESMO members enjoy including access to OncologyPRO, subscription to Annals (...) chronic myeloproliferative neoplasms • Myelodysplastic syndromes • Hodgkin's lymphoma • Primary cutaneous lymphoma • Acute myeloblastic leukaemia in adult patients • Waldenstrom's macroglobulinaemia • Gastric marginal zone lymphoma of MALT type Head and Neck Cancers Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck Hereditary Syndromes Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes Lung and Chest Tumours Early and locally

European Society for Medical Oncology2017